FIC20230040I1 - Koostumus käsittäen: sedatsuridiinia tai tämän farmaseuttisesti hyväksyttävää suolaa; ja desitabiinia. - Google Patents

Koostumus käsittäen: sedatsuridiinia tai tämän farmaseuttisesti hyväksyttävää suolaa; ja desitabiinia.

Info

Publication number: FIC20230040I1
Authority: FI; Finland
Prior art keywords: sedazuridine; decitabine; composition; pharmaceutically acceptable; acceptable salt
Prior art date: 2007-10-16

Application number

FIC20230040C

Other languages

English (en)

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-16

Filing date

2023-12-22

Publication date

2023-12-22

2023-12-22 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

2023-12-22 Publication of FIC20230040I1 publication Critical patent/FIC20230040I1/fi

Links

XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 title 1
229960003603 decitabine Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FIC20230040C 2007-10-16 2023-12-22 Koostumus käsittäen: sedatsuridiinia tai tämän farmaseuttisesti hyväksyttävää suolaa; ja desitabiinia. FIC20230040I1 (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98039707P	2007-10-16	2007-10-16
PCT/US2008/080163 WO2009052287A1 (en)	2007-10-16	2008-10-16	2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Publications (1)

Publication Number	Publication Date
FIC20230040I1 true FIC20230040I1 (fi)	2023-12-22

Family

ID=40251685

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FIC20230040C FIC20230040I1 (fi)	2007-10-16	2023-12-22	Koostumus käsittäen: sedatsuridiinia tai tämän farmaseuttisesti hyväksyttävää suolaa; ja desitabiinia.
FIC20230039C FIC20230039I1 (fi)	2007-10-16	2023-12-22	Sedatsuridiini tai tämän farmaseuttisesti hyväksyttävä suola

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
FIC20230039C FIC20230039I1 (fi)	2007-10-16	2023-12-22	Sedatsuridiini tai tämän farmaseuttisesti hyväksyttävä suola

Country Status (39)

Country	Link
US (4)	US8268800B2 (fi)
EP (2)	EP2447272B1 (fi)
JP (2)	JP5496899B2 (fi)
KR (1)	KR101543049B1 (fi)
CN (1)	CN101827856B (fi)
AT (1)	ATE548374T1 (fi)
BR (1)	BRPI0818672B8 (fi)
CA (1)	CA2702274C (fi)
CO (1)	CO6270330A2 (fi)
CR (1)	CR11427A (fi)
CY (3)	CY1112781T1 (fi)
DK (1)	DK2207786T3 (fi)
EA (1)	EA018757B1 (fi)
EC (1)	ECSP10010095A (fi)
ES (2)	ES2384011T3 (fi)
FI (2)	FIC20230040I1 (fi)
FR (2)	FR23C1052I1 (fi)
GT (1)	GT201000088A (fi)
HK (1)	HK1146410A1 (fi)
HR (1)	HRP20120419T1 (fi)
HU (2)	HUS2300045I1 (fi)
IL (1)	IL204732A (fi)
JO (1)	JO2778B1 (fi)
ME (1)	ME00997B (fi)
MX (1)	MX2010004109A (fi)
MY (1)	MY147970A (fi)
NI (1)	NI201000055A (fi)
NL (1)	NL301256I2 (fi)
NO (2)	NO2023047I1 (fi)
NZ (1)	NZ584229A (fi)
PL (1)	PL2207786T3 (fi)
PT (1)	PT2207786E (fi)
RS (1)	RS52323B (fi)
SA (1)	SA08290661B1 (fi)
SI (1)	SI2207786T1 (fi)
TW (1)	TWI445539B (fi)
UA (1)	UA99476C2 (fi)
WO (1)	WO2009052287A1 (fi)
ZA (1)	ZA201002178B (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain vehicles, installations and methods
HUE064677T2 (hu)	2008-05-15	2024-04-28	Celgene Corp	Citidin-analógokat tartalmazó orális készítmények és eljárások azok alkalmazására
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
US20100055047A1 (en) *	2008-08-26	2010-03-04	Yiyu Zou	Methods for treating bronchial premalignancy and lung cancer
CL2009002206A1 (es) *	2008-12-23	2011-08-26	Gilead Pharmasset Llc	Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
US8329665B2 (en)	2009-04-06	2012-12-11	Eisai Inc.	Compositions and methods for treating cancer
JP5687687B2 (ja)	2009-04-06	2015-03-18	大塚製薬株式会社	癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
US8609631B2 (en)	2009-04-06	2013-12-17	Eisai Inc.	Compositions and methods for treating cancer
ES2628580T3 (es) *	2009-04-06	2017-08-03	Otsuka Pharmaceutical Co., Ltd.	Combinación de decitabina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer el tratamiento de cáncer
GB0907551D0 (en)	2009-05-01	2009-06-10	Univ Dundee	Treatment or prophylaxis of proliferative conditions
TWI598358B (zh)	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
PE20130151A1 (es)	2010-03-31	2013-02-21	Gilead Pharmasset Llc	Sintesis estereoselectiva de activos que contienen fosforo
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
TW201242974A (en)	2010-11-30	2012-11-01	Gilead Pharmasset Llc	Compounds
MD4589C1 (ro)	2011-09-16	2019-03-31	Gilead Pharmasset Llc	Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
EA029081B9 (ru)	2013-01-31	2018-09-28	Джилид Фармассет Ллс	Комбинированный состав двух противовирусных соединений
CA2921160C (en)	2013-08-27	2021-04-13	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
AU2014342402B2 (en)	2013-10-29	2018-11-01	Otsuka Pharmaceutical Co., Ltd.	Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
MX2016013027A (es)	2014-04-04	2017-05-23	Del Mar Pharmaceuticals	Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
EP3925609A1 (en)	2014-08-22	2021-12-22	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
EP3960182A1 (en) *	2015-12-03	2022-03-02	Epidestiny, Inc.	Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
WO2017158396A1 (en)	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cytidine deaminase inhibitors for the treatment of pancreatic cancer
PE20210367A1 (es)	2018-02-02	2021-02-26	Maverix Oncology Inc	Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
US11224610B2 (en) *	2018-09-19	2022-01-18	Otsuka Pharmaceutical Co., Ltd.	Low dose combination CDA substrate drug/cedazuridine with extended administration
US20210388361A1 (en) *	2018-10-19	2021-12-16	Interoligo Corporation	Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
CN112888700A (zh) *	2018-10-19	2021-06-01	因特欧力多公司	具有改善治疗功效的修饰核酸和含有其的抗癌药物组合物
JP2022552817A (ja) *	2019-10-08	2022-12-20	大塚製薬株式会社	高純度の２’－デオキシ－２’，２’－ジフルオロテトラヒドロウリジン及びその製造方法
CA3163122A1 (en) *	2020-02-25	2021-09-02	Aram Oganesian	Combination decitabine and cedazuridine solid oral dosage forms
WO2022204126A1 (en) *	2021-03-26	2022-09-29	The Cleveland Clinic Foundation	Treatment of rna virus infection with a cytidine deaminase inhibitor
WO2022254457A1 (en) *	2021-05-29	2022-12-08	Msn Laboratories Private Limited, R&D Center	An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
AU2022370354A1 (en)	2021-10-19	2024-05-30	Akirabio, Inc.	Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023076332A1 (en) *	2021-11-01	2023-05-04	St. John's University	Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) *	2021-12-25	2023-08-31	Scinopharm Taiwan, Ltd.	Process for preparing cedazuridine
WO2024047394A1 (en)	2022-08-31	2024-03-07	Otsuka Pharmaceutical Co., Ltd.	Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4017606A (en) *	1973-10-04	1977-04-12	The Upjohn Company	Organic compounds and process
US4210638A (en) *	1978-03-17	1980-07-01	Pcr, Inc.	Antiviral composition and method of treating virus diseases
US4275057A (en)	1980-01-28	1981-06-23	The United States Of America As Represented By The Department Of Health, Education And Welfare	Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en)	1983-03-10	1985-07-02	Eli Lilly And Company	Difluoro antivirals and intermediate therefor
JPS61500224A (ja)	1983-10-26	1986-02-06	グリ−ル、シエルダン　ビ−	腫瘍性組織を放射線に対して増感する医薬組成物
DE3587500T2 (de)	1984-12-04	1993-12-16	Lilly Co Eli	Tumorbehandlung bei Säugetieren.
US4965374A (en)	1987-08-28	1990-10-23	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en)	1987-08-28	1993-06-29	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en)	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
EP0543976A4 (en)	1991-04-23	1993-11-10	Oglevee, Ltd.	In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr)	1991-10-08	1993-12-10	Commissariat A Energie Atomique	Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en)	1992-06-22	1994-12-06	Eli Lilly And Company	Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en)	1992-06-22	1997-01-14	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5606048A (en)	1992-06-22	1997-02-25	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en)	1992-06-22	1995-06-20	Eli Lilly And Company	Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en)	1992-06-22	1998-10-13	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
WO1994019362A1 (en)	1993-02-23	1994-09-01	City Of Hope	4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en) *	1993-05-14	1994-11-24	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en)	1993-06-01	1993-07-21	Hafslund Nycomed As	Cell growth regualtors
US5637688A (en)	1994-12-13	1997-06-10	Eli Lilly And Company	Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en)	1995-01-18	1996-05-28	Eli Lilly And Company	2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
AU5300396A (en) *	1995-03-01	1996-09-18	Human Gene Therapy Research Institute	Radiation enhanced gene therapy for treatment of tumors
US6001994A (en)	1995-12-13	1999-12-14	Eli Lilly And Company	Process for making gemcitabine hydrochloride
US5760208A (en)	1996-08-14	1998-06-02	The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations	Process to prepare pyrimidine nucleosides
EP1156827B1 (en)	1999-03-01	2006-09-20	Halogenetics, Inc.	USE OF COMPOSITIONS COMPRISING CldC AS RADIOSENSITIZERS IN THE TREATMENT OF NEOPLASTIC DISEASES
US6933287B1 (en)	1999-03-01	2005-08-23	Sheldon B. Greer	Dramatic simplification of a method to treat neoplastic disease by radiation
MXPA02002088A (es)	1999-08-26	2003-09-22	Aortech Internat Plc	Mejoras en relacion al posicionamiento del cateter.
US6462191B1 (en)	2000-07-13	2002-10-08	Air Products And Chemicals, Inc.	Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN102241720B (zh)	2000-11-29	2014-01-29	三井化学株式会社	L-核酸衍生物及其合成方法
ATE290882T1 (de)	2001-01-16	2005-04-15	Glaxo Group Ltd	Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
EP2322534A1 (en)	2001-05-18	2011-05-18	Rakesh Kumar	Antiviral nucleosides
AU2002322805B2 (en) *	2001-07-31	2007-11-08	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Inhibitor of DNA methylation
US20040002476A1 (en)	2002-02-14	2004-01-01	Stuyver Lieven J.	Modified fluorinated nucleoside analogues
US6982253B2 (en)	2002-06-05	2006-01-03	Supergen, Inc.	Liquid formulation of decitabine and use of the same
EP1545558A4 (en)	2002-09-24	2010-02-17	Koronis Pharmaceuticals Inc	1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US7265096B2 (en)	2002-11-04	2007-09-04	Xenoport, Inc.	Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2005115410A2 (en)	2004-05-06	2005-12-08	University Of Rochester	Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en)	2004-07-13	2006-01-19	Supergen Inc.	Compositions and formulations of decitabine polymorphs and methods of use thereof
WO2006015346A1 (en)	2004-07-30	2006-02-09	Pharmaessentia Corp.	STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
WO2006063105A1 (en)	2004-12-08	2006-06-15	Sicor Inc.	Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) *	2006-11-27	2008-07-17	University Of Miami	Designer theraphy of pancreatic tumors
WO2009021551A1 (en)	2007-08-13	2009-02-19	Universite De La Mediterranee	A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain vehicles, installations and methods
WO2010047698A1 (en)	2008-10-22	2010-04-29	University Of Alabama At Birmingham	Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
US8609631B2 (en)	2009-04-06	2013-12-17	Eisai Inc.	Compositions and methods for treating cancer
US8329665B2 (en)	2009-04-06	2012-12-11	Eisai Inc.	Compositions and methods for treating cancer
JP5687687B2 (ja)	2009-04-06	2015-03-18	大塚製薬株式会社	癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
ES2628580T3 (es)	2009-04-06	2017-08-03	Otsuka Pharmaceutical Co., Ltd.	Combinación de decitabina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer el tratamiento de cáncer

2008
- 2008-10-14 JO JO2008459A patent/JO2778B1/en active
- 2008-10-15 TW TW097139594A patent/TWI445539B/zh active
- 2008-10-16 ES ES08840633T patent/ES2384011T3/es active Active
- 2008-10-16 KR KR1020107010621A patent/KR101543049B1/ko active IP Right Grant
- 2008-10-16 RS RS20120232A patent/RS52323B/en unknown
- 2008-10-16 PL PL08840633T patent/PL2207786T3/pl unknown
- 2008-10-16 SI SI200830624T patent/SI2207786T1/sl unknown
- 2008-10-16 BR BRPI0818672A patent/BRPI0818672B8/pt active IP Right Grant
- 2008-10-16 EP EP12151552.2A patent/EP2447272B1/en active Active
- 2008-10-16 US US12/252,961 patent/US8268800B2/en active Active
- 2008-10-16 DK DK08840633.5T patent/DK2207786T3/da active
- 2008-10-16 AT AT08840633T patent/ATE548374T1/de active
- 2008-10-16 PT PT08840633T patent/PT2207786E/pt unknown
- 2008-10-16 CA CA2702274A patent/CA2702274C/en active Active
- 2008-10-16 EA EA201000642A patent/EA018757B1/ru unknown
- 2008-10-16 WO PCT/US2008/080163 patent/WO2009052287A1/en active Application Filing
- 2008-10-16 MX MX2010004109A patent/MX2010004109A/es active IP Right Grant
- 2008-10-16 JP JP2010530110A patent/JP5496899B2/ja active Active
- 2008-10-16 CN CN2008801117195A patent/CN101827856B/zh active Active
- 2008-10-16 NZ NZ584229A patent/NZ584229A/en unknown
- 2008-10-16 MY MYPI2010001528A patent/MY147970A/en unknown
- 2008-10-16 EP EP08840633A patent/EP2207786B1/en active Active
- 2008-10-16 UA UAA201003977A patent/UA99476C2/ru unknown
- 2008-10-16 ME MEP-2010-68A patent/ME00997B/me unknown
- 2008-10-16 ES ES12151552.2T patent/ES2616566T3/es active Active
- 2008-10-18 SA SA08290661A patent/SA08290661B1/ar unknown
2010
- 2010-01-26 ZA ZA2010/02178A patent/ZA201002178B/en unknown
- 2010-03-25 IL IL204732A patent/IL204732A/en active IP Right Grant
- 2010-04-09 EC EC2010010095A patent/ECSP10010095A/es unknown
- 2010-04-12 GT GT201000088A patent/GT201000088A/es unknown
- 2010-04-14 NI NI201000055A patent/NI201000055A/es unknown
- 2010-05-12 CR CR11427A patent/CR11427A/es unknown
- 2010-05-13 CO CO10057462A patent/CO6270330A2/es active IP Right Grant
2011
- 2011-01-20 HK HK11100565.2A patent/HK1146410A1/xx unknown
2012
- 2012-05-16 HR HRP20120419AT patent/HRP20120419T1/hr unknown
- 2012-05-24 CY CY20121100467T patent/CY1112781T1/el unknown
- 2012-07-24 US US13/556,404 patent/US8618075B2/en active Active
2013
- 2013-11-25 US US14/088,465 patent/US8951987B2/en active Active
2014
- 2014-03-05 JP JP2014043175A patent/JP5859588B2/ja active Active
- 2014-12-29 US US14/584,437 patent/US9567363B2/en active Active
2023
- 2023-12-21 NO NO2023047C patent/NO2023047I1/no unknown
- 2023-12-21 NO NO2023048C patent/NO2023048I1/no unknown
- 2023-12-21 HU HUS2300045C patent/HUS2300045I1/hu unknown
- 2023-12-21 HU HUS2300044C patent/HUS2300044I1/hu unknown
- 2023-12-22 FI FIC20230040C patent/FIC20230040I1/fi unknown
- 2023-12-22 CY CY2023029C patent/CY2023029I1/el unknown
- 2023-12-22 FI FIC20230039C patent/FIC20230039I1/fi unknown
- 2023-12-22 CY CY2023028C patent/CY2023028I1/el unknown
- 2023-12-26 FR FR23C1052C patent/FR23C1052I1/fr active Active
- 2023-12-26 FR FR23C1051C patent/FR23C1051I1/fr active Active
- 2023-12-27 NL NL301256C patent/NL301256I2/nl unknown

Also Published As

Publication number	Publication date
NZ584229A (en)	2012-06-29
CA2702274A1 (en)	2009-04-23
ZA201002178B (en)	2011-05-25
NI201000055A (es)	2010-08-13
EP2447272A1 (en)	2012-05-02
UA99476C2 (en)	2012-08-27
AU2008312435B2 (en)	2014-04-17
DK2207786T3 (da)	2012-06-18
EP2447272B1 (en)	2017-02-01
GT201000088A (es)	2012-03-13
EP2207786A1 (en)	2010-07-21
US8268800B2 (en)	2012-09-18
CY2023028I1 (el)	2024-02-16
EP2207786B1 (en)	2012-03-07
JO2778B1 (en)	2014-03-15
WO2009052287A1 (en)	2009-04-23
IL204732A (en)	2013-07-31
IL204732A0 (en)	2010-11-30
HUS2300045I1 (hu)	2024-01-28
RS52323B (en)	2012-12-31
BRPI0818672A2 (pt)	2015-04-14
CN101827856B (zh)	2013-02-06
PL2207786T3 (pl)	2012-09-28
TW200924786A (en)	2009-06-16
US20090137521A1 (en)	2009-05-28
JP2011500713A (ja)	2011-01-06
HK1146410A1 (en)	2011-06-03
BRPI0818672B1 (pt)	2020-10-20
HRP20120419T1 (hr)	2012-07-31
KR101543049B1 (ko)	2015-08-07
TWI445539B (zh)	2014-07-21
NO2023048I1 (en)	2023-12-21
CR11427A (es)	2010-08-16
SI2207786T1 (sl)	2012-10-30
ATE548374T1 (de)	2012-03-15
FR23C1051I1 (fr)	2024-01-26
ES2616566T3 (es)	2017-06-13
JP2014177455A (ja)	2014-09-25
PT2207786E (pt)	2012-05-28
AU2008312435A8 (en)	2014-07-24
US9567363B2 (en)	2017-02-14
US20120289475A1 (en)	2012-11-15
ES2384011T3 (es)	2012-06-28
BRPI0818672B8 (pt)	2021-05-25
AU2008312435A1 (en)	2009-04-23
NO2023047I1 (no)	2023-12-21
HUS2300044I1 (hu)	2024-01-28
KR20100091978A (ko)	2010-08-19
CN101827856A (zh)	2010-09-08
SA08290661B1 (ar)	2012-06-10
MY147970A (en)	2013-02-28
ECSP10010095A (es)	2010-07-30
JP5496899B2 (ja)	2014-05-21
US20140186335A1 (en)	2014-07-03
US20150210730A1 (en)	2015-07-30
CA2702274C (en)	2015-12-29
MX2010004109A (es)	2010-08-10
NL301256I2 (nl)	2024-01-11
FR23C1052I1 (fr)	2024-01-26
ME00997B (me)	2012-10-20
US8951987B2 (en)	2015-02-10
CY2023029I1 (el)	2024-02-16
JP5859588B2 (ja)	2016-02-10
EA018757B1 (ru)	2013-10-30
EA201000642A1 (ru)	2010-10-29
CY1112781T1 (el)	2016-02-10
US8618075B2 (en)	2013-12-31
FIC20230039I1 (fi)	2023-12-22
CO6270330A2 (es)	2011-04-20
NL301256I1 (fi)	2024-01-03

Publication	Publication Date	Title
FIC20230040I1 (fi)	2023-12-22	Koostumus käsittäen: sedatsuridiinia tai tämän farmaseuttisesti hyväksyttävää suolaa; ja desitabiinia.
NO2022057I1 (no)	2022-12-13	Capmatinib or a pharmaceutically acceptable salt thereof
NO2019027I1 (no)	2019-07-04	kobicistat eller et farmasøytisk akseptabelt salt derav
NO2020038I1 (no)	2020-11-18	Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
LTPA2018005I1 (lt)	2018-02-12	Farmacinė kompozicija
NO2016016I1 (no)	2016-08-17	Lesinurad, eller et farmasøytisk akseptabelt salt derav
BRPI0810928A2 (pt)	2019-09-24	"composição farmacêutica"
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
BRPI0714539A2 (pt)	2014-02-25	"formas farmacêuticas"
BRPI0721651A2 (pt)	2014-04-01	Composição farmacêutica
BRPI0716325A2 (pt)	2014-03-04	Composição antimicrobianas
ATE469145T1 (de)	2010-06-15	4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
RU2398586C3 (ru)	2017-10-04	Фармацевтическая композиция
FR2899479B1 (fr)	2009-07-24	Composition cicatrisante
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
BRPI0719398A2 (pt)	2015-03-31	Composição farmacêutica.
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
FI20060217A0 (fi)	2006-03-06	Sprinkleri
DK2120884T3 (da)	2011-02-07	Farmaceutisk sammensætning
DE602007001681D1 (de)	2009-09-03	1,3-dioxan-carboxylsäuren
FIU20060412U0 (fi)	2006-10-04	Suojaliivi
IT1393655B1 (it)	2012-05-08	Composizione pesticida
FR2898899B1 (fr)	2012-09-28	Composition photoreticulable
IT1393651B1 (it)	2012-05-08	Composizione pesticida